Arg-Gly-Asp (RGD)-and fibrinogen y-chain carboxyterminal (GQQHHLGGAKQAGDV) peptides inhibit fibrinogen, fibronectin (Fn), vitronectin, and von Willebrand factor (vWF) binding to the platelet glycoprotein Ilb-Illa complex (GP lIbII1a). GP Ilb-IIIa, vWF, and Fn are essential for normal platelet adherence to subendothelium. We added peptides to normal citrated whole blood before perfusion over human umbilical artery subendothelium and evaluated platelet adherence morphometrically at high (2,600 s-') and low (800 s-') wall shear rates. We also examined the effects of the peptides on platelet adhesion to collagen in a static system. At the high wall shear rate, RGDS and GQQHHLGGAKQAGDV caused dose-dependent reduction in the surface coverage with spread and adherent platelets. Amino acid transposition and conservative substitutions of RGD peptides and the AGDV peptide significantly inhibited platelet adherence at 2,600 s-'. By contrast, the modified RGD peptides and AGDV do not affect adhesive protein binding to platelets. None of the native or modified RGD-or fibrinogen y-chain peptides significantly inhibited either platelet adherence to subendothelium at 800 s-' or platelet adhesion to collagen. Our findings demonstrate that peptides that interfere with adhesive protein binding to GP Ub-Illa inhibit platelet adherence to vascular subendothelium with flowing blood only at high wall shear rates. Platelet adherence to subendothelium at high wall shear rates appears to be mediated by different recognition specificities from those required for fluid-phase adhesive protein binding or static platelet adhesion. (J. Clin. Invest. 1990Invest. . 86:1715Invest. -1722
Introduction
The plasma adhesive proteins fibrinogen (Fg),' fibronectin (Fn), von Willebrand factor (vWF), and vitronectin (Vn) each contain an Arg-Gly-Asp (RGD) sequence (1) (2) (3) (4) (5) . Natural and synthetic RGD-containing peptides have been shown to inhibit Fg, Fn, vWF, and Vn binding to the platelet glycoprotein Ilb-Illa complex (GP Ilb-Illa) in a competitive and reversible manner (6) (7) (8) (9) (10) (11) . Similarly, dodeca-and pentadecapeptides (Gly-Gln-Gln-His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-GlyAsp-Val) (GQQHHLGGAKQAGDV) of the carboxyl terminus of the Fg y-chain inhibit Fg, Fn, and vWF binding to platelets (1 1-13) . Both RGD-and Fg 7-chain peptides have been shown to alter the conformation of purified GP Ilb-Illa (14) . Haverstick et al. (9) , using a static system, showed that platelet adhesion to Fn, Fg, and vWF substrates was inhibited by RGD-containing peptides (9) . Amino acid transposition or conservative substitutions led to a loss of the peptides' ability to inhibit both adhesive protein binding to platelets and platelet adhesion (6, (8) (9) (10) (11) . It was also found that the terminal tetrapeptide of the Fg y-chain (AGDV) lacks the inhibitory activity of the dodeca-or pentadecapeptide (8, 1 
1).
We and others have demonstrated that GP Ilb-IIIa plays a role in platelet adherence to subendothelium in flowing blood, (15, 16) and vWF and Fn are required for normal platelet adherence (17, 18) . To examine the effect of RGD-and Fg 7-chain peptides on platelet adherence to human arterial subendothelium with flowing blood, we have used the technique of Baumgartner and Muggli (19) with normal citrated whole blood to which the native, substituted, or transposed peptides were added. We compared platelet adherence to human arterial subendothelium at a high (2,600 s-') and low (800 s-') wall shear rate. We also tested the peptides' effects upon platelet adhesion to collagen in a static system. These experiments were performed to define whether shear-dependent alterations in GP lib-Illa-mediated platelet adherence could be identified.
Methods
Perfusion procedure and morphologic evaluation. Human umbilical arteries were dissected free from umbilical cords obtained immediately after birth. The arterial segments were everted and de-endothelialized by brief exposure to air and further prepared as previously described (15) . For perfusion experiments, the arterial segments were placed in an annular perfusion chamber similar to those developed by Baumgartner and Muggli (19) . The chamber contained a rod on which the everted vascular segments were mounted such that the blood entering plasma; RCD, Ringer's citrate buffer with dextrose; Vn, vitronectin; vWF, von Willebrand factor. Additionally, amino acids are encoded according to the following system: A, alanine; R, arginine; D, aspartic acid; C, cysteine; E, glutamic acid; Q, glutamine; G, glycine; H, histidine; L, leucine; K, lysine; M, methionine; F, phenylalanine; S, serine; T, threonine; V, valine. the chamber flowed through the annular space between the subendothelial surface and the chamber wall, thereby exposing the subendothelium to platelets. The perfusion conditions and rheologic parameters were as previously described (15) , and the perfusions were performed at 370C for 5 min at a flow rate of either 300 ml/min, producing a wall shear rate of 2,600 s-', or 90 ml/min, leading to a wall shear rate of 800 s-'. The wall shear rates were calculated according to Turitto and Baumgartner (20) . The higher wall shear rate closely approximates conditions physiologically present in the microvasculature, or in partially occluded arteries, whereas 800 s-' is similar to rheologic parameters present in large arteries (21) .
The donors were laboratory personnel who had no bleeding history and were not receiving medications that interfered with platelet function. As measured by an electronic counting device (model S Plus, Coulter Electronics, Inc., Hialeah, FL), the mean pre-perfusion values (and ranges) were as follows: hematocrit, 40.1% (35.7%-45.5%) and platelet count, 338,000/,ul (251,000-405,000/Ml). All blood was collected into sodium citrate (final whole-blood concentration 10.88 mM). A portion of the citrated blood drawn from each donor was used in its native state for control perfusions, whereas synthetic peptides were added to other aliquots ofthe sample. Each peptide was incubated with the blood for 15 min at 370C, and the control perfusates were also incubated for 15 min at 370C, before perfusions.
After a perfusion experiment, the arterial segment was washed, fixed, sectioned, histologically processed, and embedded in epoxy resin, as previously described (15) . Each 0.8-gm section was evaluated morphometrically by light microscopy by a single individual who was unaware of the experimental or control group to which it corresponded. The morphometric parameters employed were those of Baumgartner and Muggli (19) . The platelet-surface interaction was categorized as either C, contact platelets attached but not spread along the surface, or S, platelets spread along the subendothelium. The latter category may include spread platelets with superimposed platelet thrombi, which are defined as collections of platelets extending 5 gm or more in height above the subendothelial surface. Total platelet adherence was defined as C + S, and each parameter was expressed as a percentage of the total number of points counted (-1,500) per vessel segment. Values are expressed as the mean±SEM. Student's t test was used to evaluate the significance of differences between mean values (22). Differences were considered statistically significant if P < 0.05.
Evaluation ofvWF binding to thrombin-stimulated platelets. Platelets were separated from whole blood by centrifugation through a discontinuous arabinogalactan gradient as previously described (1 1).
vWF was purified from normal cryoprecipitate by gel chromatography on Sepharose 4B as described (1 1). It was radioiodinated with 1251 by the immobilized lactoperoxidase method (1 1). The platelets were activated by 0.1 U/ml thrombin, the thrombin was neutralized by a twofold excess of hirudin, and the radiolabeled vWF was incubated with platelets in the presence of various concentrations of RGD-or Fg 'y-chain peptides for 30 min at 24°C, as described (11) . The peptides employed in these studies were of the same lot numbers as those used in perfusion experiments. Bound radiolabeled vWF was separated from the free vWF by centrifugation through a 10% arabinogalactan gradient for 3 min in a Microfuge (Beckman Instruments, Inc., Fullerton, CA) at 12,000 g. The tips of the centrifuge tubes were cut off and counted for 1251 in a -y-counter. Nonspecific binding to platelets was determined in the presence ofa 100-fold excess ofunlabeled vWF, and represented < 4% of the total vWF bound. The concentration of each peptide which inhibited 50% ofthe control vWF binding, i.e., the IC", was determined for each peptide.
Preparation of monomeric type I collagen. Type I collagen was isolated from commercial crude preparations of calf skin acid-soluble type I collagen (Sigma Chemical Co., St. Louis, MO) by extraction in 0.5 mol/liter acetic acid at 4°C. The extracted material was precipitated by 4% NaCl, and was redissolved in 0.5 mol/liter acetic acid at 4°C. It was dialyzed for 24 h against 0.02 mol/liter sodium phosphate, pH 9.0, until the pH ofthe retained material was > 7.0. The precipitate was then collected by centrifugation at 4VC for 30 min at 7,500 g, redissolved in 0.1 mol/liter acetic acid, and dialyzed against 0.02 mol/ liter sodium phosphate buffer, pH 9.0. The collagen solution was lyophilized and frozen at -70'C until used.
Before use, the lyophilized collagen was dissolved in 10 ml of 5.0 mmol/liter acetic acid by gentle mixing overnight at 40C. It was centrifuged at 100,000 g for 1 h at 40C. This preparation was stable at 40C for several weeks (23) .
Plate preparation. Immulon No. 2 Removawells (Dynatech, Inc., Chantilly VA) were coated with 50 Ml of collagen diluted in 5.0 mmol/ liter acetic acid to a final concentration of 5 Mg per well. Plates were incubated in a humidity chamber at 40C overnight or for 3 h at 240C. The collagen was removed by gentle aspiration, and the wells were blocked with 50 mmol/liter Tris-HCI which contained 5 mmol/liter CaCI2, 1% bovine serum albumin (BSA), 0.1 mmol/liter phenylmethylsulfonyl fluoride, 0.02% NaN3, pH 7.8, for 30-60 min at 240C.
The blocking buffer was aspirated, and the wells were washed three times in 50 mmol/liter Tris-HC1 containing 140 mmol/liter NaCI, 5 mmol/liter glucose, 2 mmol/liter MgCI2, 5 mg/ml BSA, and 20 ng/ml prostaglandin E, (PGE,).
Platelet preparation. Blood was drawn from normal donors using a two-syringe technique with a 19-gauge infusion set and polypropylene syringes. The first syringe containing 3-5 ml ofblood was discarded. 10 ml of blood was drawn into a second syringe containing 1.4 ml of acid citrate dextrose-A anticoagulant, pH 5.1. It was gently mixed and transferred to a polypropylene tube.
Platelet-rich plasma (PRP) was prepared by centrifugation at 240C for 3 min at 750 g. The PRP was removed and divided into two equal portions in polypropylene tubes. Each of the two tubes of PRP was diluted to 12 ml with Ringer's citrate buffer containing glucose and PGEI (RCD-PGE,: 71.9 mmol/liter NaCl, 0.7 mmol/liter KCI, 0.6 mmol/liter CaCI2, 0.8 mmol/liter NaHCO3, 20.0 mmol/liter trisodium citrate dihydrate, 27.8 mmol/liter glucose, 43 ng/ml PGE,, pH 6.5) and was centrifuged at 24°C for 12 min at 1,100 g. The wash was discarded and the platelet pellets were resuspended in 500 M1 of RCD-POE1, using a 200-Ml pipette (Rainin Instrument Co., Inc., Woburn, MA). Each of the two tubes was diluted to 12 ml with RCD-PGE, and was centrifuged at 24°C for 12 min at 1,100 g.
After centrifugation, the wash was discarded and the platelets were resuspended in 500 ul of RCD without PGE1. The two tubes of platelets were pooled, and an additional 1-2 ml of RCD without PGE, was added.
Labeling and platelet adhesion assay. Platelets were labeled by the addition of 300-400 MCi of ["'In] oxyquinoline (Amersham Corp., Arlington Heights, IL). After incubation at 24°C for 15-30 min, unbound "'In was removed by diluting the platelet suspension to 12 ml with Hepes buffer with PGE, (137 mmol/liter NaCI, 2.7 mmol/liter KC1, 4 mmol/liter MgCI2-6H20, 3.75 mmol/liter NaH2PO4, 3.8 mmol/liter hepes, 43 ng/ml PGE,, 0.35% BSA, 5.56 mmol/liter glucose, pH 7.35), and centrifuging them at 24°C for 12 min at 1,100 g. After centrifugation, the labeled platelets were resuspended in Hepes buffer without PGE,. They were counted using a Cellozone cell counter (Particle Data, Inc., Elmhurst, IL).
Equal volumes of platelet suspension and peptide diluted in saline (0.145 mol/liter NaCI) were incubated for 20 min at 24°C in 12 X 75-mm polystyrene tubes. 50 Ml of the platelet-peptide or plateletsaline mixture was added to each collagen-coated well. The final platelet concentration was S X I05 platelets per well. Control wells included blank, 1% BSA-, and poly-L-lysine (1 mg/100 ml in PBS)-coated wells. Minimal platelet binding was observed to blank wells or wells to which 1% BSA was added, and maximal binding was observed to poly-L-lysine-coated wells. After incubation for 1 h at 24°C, the wells were washed three times with 50 mmol/liter Tris-HCI buffer containing 140 mmol/liter NaCI, 5 mmol/liter glucose, 2 mmol/liter MgCl2, 5 mg/ml BSA, 20 ng/ml PGE,, pH 7.6, using an Eppendorf repeater pipette (Brinkmann Instruments, Inc., Westbury, NY) to dispense 100 Ml of wash buffer into each well, and a digital multichannels pipette (Flow Laboratories, Elflab, Finland) to aspirate from the wells.
The wells were transferred to counting tubes and were counted for Bachem Fine Chemicals, Torrance, CA (GQQHHLGGAKQAGDV, VGSE, LG, MFM) or Peninsula Laboratories, Inc., Belmont, CA (all other peptides). The peptides were homogenous by high-performance liquid and thin-layer chromatography, and the amino acid analysis of each peptide was consistent with its predicted composition (assays performed by the suppliers). Each peptide was dissolved in distilled, deionized water at a concentration of 1.25-5 mg/ml immediately before being added to citrated whole blood. The volume of dissolved peptide added to the whole blood was < 5% ofthe whole-blood volume in all experiments (i.e., 100-1,100 Ml of peptide added to the 25-ml blood perfusate 
Results
Inhibition of platelet adherence by peptides containing the RGDS sequence at high wall shear rate (2,600 s'). Control perfusions with citrated whole blood from normal donors gave values for total platelet adherence (C + S) approximating 55% coverage of the subendothelial surface (Table I and Fig. 1 ). Platelet thrombi occupied 0.9±0.2% of the surface. When a control peptide, either Val-Gly-Ser-Glu (VGSE), Leu-Gly (LG), or Met-Phe-Met (MFM), was added to the blood, each of the parameters of platelet adherence was unchanged (Table I) . However, RGDS caused dose-dependent reduction of surface coverage with spread platelets (S) and C + S, as well as a small but statistically significant reduction in surface coverage with contact platelets (C) ( Table I and Fig. 1 ). When longer peptides containing the RGDS sequence were used, S and C + S were also significantly inhibited (Table I) . However, GRGDS and RGDSPASSKP were somewhat less potent than the tetrapeptide (Tables I and II (2,600 s-). Conservative amino acid substitution ofthreonine for serine in the fourth position (RGDT) did not significantly impair the peptide's capacity to inhibit S and C + S at a wall shear rate of 2,600 s-' (Table I) . Similarly, substitution with cysteine in the fourth position (RGDC) produced a peptide that retained the ability to interfere with platelet adherence, although at 50 Mmol/liter it caused a 33% reduction in C + S, compared with the 63% reduction produced by RGDS (Table I). Peptide Concentration (1imol/Iiter) Figure 1 . Inhibition of platelet adherence to arterial subendothelium by RGDS and the fibrinogen -y-chain carboxyterminal pentadecapeptide. Perfusions were performed as described in the legend to Table I with RGDS ( ), GQQHHLGGAKQAGDV (-SDGRG (. ), or RGES (-* -*---) added to citrated whole blood at the indicated concentrations. Bars indicate±SEM. Since in other systems conservative substitutions in the RGD sequence have been shown to cause a loss of peptide inhibitory activity (6, (8) (9) (10) (11) , we used Arg-Gly-Glu-Ser (RGES), Gly-Arg-Ala-Asp-Ser-Pro (GRADSP), and Lys-GlyAsp-Ser (KGDS). We also used Arg-Phe-Asp-Ser (RFDS) and Arg-Glu-Asp-Val (REDV), having selected the latter peptide to examine the effect of two substitutions in the RGDS sequence. In each case, the substituted peptide's capacity to significantly inhibit platelet adherence to subendothelium at the high wall shear rate was retained (Table I) . Reversal of the native sequence produced peptides that significantly reduced S and C + S (Table I ). In fact, Ser-Asp-Gly-Arg-Gly (SDGRG) showed inhibitory activity nearly equal to that of RGDS (Tables I and II) . None of these peptides produced statistically significant changes in platelet thrombi, compared with controls. The maximal inhibition of C + S observed in all the experiments was the 67% reduction produced by 50 mol/liter RGDS (Table II) .
Inhibition of platelet adherence to subendothelium by fibrinogen gamma chain carboxyterminal peptides at high wall shear rate (2,600 s-'). The Fg y-chain carboxyterminal pentadecapeptide, GQQHHLGGAKQAGDV, caused inhibition of S and C + S at the high wall shear rate similar to that observed with RGDS (Table I and Fig. 1 ). Furthermore, like RGDS, GQQHHLGGAKQAGDV also significantly reduced C (Table  I) . Unlike the situation with fluid-phase adhesive protein binding to platelets (8, 11) , the terminal tetrapeptide, AGDV, showed inhibitory activity virtually identical to that of the pentadecapeptide (Tables I and II (Tables I  and II ; Fig. 1 ). As previously reported (8, 9, 1 1), conservative substitutions and amino acid transposition in the RGD sequence led to peptides which were ineffective inhibitors of vWF binding (Table II) , despite the fact that the substituted peptides were potent inhibitors of platelet adherence (Tables I   and II (Table II) , consistent with previous reports (8, 11) . However AGDV, which was equipotent with the pentadecapeptide with respect to inhibition ofplatelet adherence, had no effect on vWF binding to thrombin-stimulated platelets (Table II) (8, 11) .
Effect of RGD-and Fg 'y-chain carboxyterminal peptides on platelet adherence to subendothelium at low wall shear rate (800 s-'). In perfusions performed at a wall shear rate of 800 s-', control experiments with citrated whole blood from normal donors gave values for C + S of -45% (Table III) . Compared with the high wall shear rate experiments, at 800 s-' subendothelial coverage with platelet thrombi was substantially higher, 15.1%±3.8%. When RGDS was added to the blood, each parameter of the platelet-subendothelial interaction at 800 s-' was unchanged, compared with controls (Table  III) ; surface coverage with platelet thrombi was 13.2±3.9%. The modified RGD peptides KGDS, RGES, and SDGRG also failed to cause statistically significant inhibition of C + S (Table III) or ofplatelet thrombus formation. The fibrinogen ' chain carboxyterminal peptide, GQQHHLGGAKQAGDV, did not alter C, S, or C + S, compared with controls (Table III) . This peptide did cause a 40% reduction in mean subendothe- Effect of RGD-and Fg y-chain carboxyterminal peptides on static platelet adhesion to collagen. In view of the profound differences in the effect of RGD-and Fg oy-chain peptides on platelet adherence to subendothelium observed between experiments performed at high and low wall shear rates, studies were performed in a nonflowing adhesion system. Native or substituted RGD peptides were added to platelets labeled with ["' In]oxyquinoline, and platelet adhesion to type I collagen immobilized in microtiter wells was measured. In contrast to previously reported studies involving platelet adhesion to immobilized vWF, Fg, or Fn (9), RGDS did not inhibit this static platelet adhesion. Furthermore, none of the modified RGD peptides studied (RGDT, RGES, KGDS, or SDGRG) had any significant effect on platelet adhesion to immobilized collagen. The Fg -y-chain carboxyterminal peptide, GQQHHL-GGAK-QAGDV, also failed to inhibit static platelet adhesion to collagen.
Discussion
It is well established that GP Ib-IIla contains the receptor site(s) that mediate(s) the binding of Fg, Fn, Vn, and vWF to thrombin-stimulated platelets (10, (24) (25) (26) (27) . vWF and Fn binding to GP Ilb-II1a is necessary for optimal platelet spreading and adhesion to artificial adhesive protein substrates in static systems (9) , and these proteins are required for normal platelet adherence to subendothelium with flowing blood (15-18).
Dedhar et al. (28) have recently demonstrated that the RGD sequence in collagen type I is essential for recognition by the collagen receptor present in osteosarcoma cells (28) . RGDand Fg y-chain peptides have been shown to inhibit Fg, Fn, Vn, and vWF binding to platelets (Table II) (6) (7) (8) (9) (10) (11) (12) (13) 27) , and platelet adhesion to subendothelium at high wall shear rates (29) , and the former peptides reduced platelet adhesion to Fg, Fn, and vWF substrates in a nonflowing assay system (9) .
We sought to determine whether these peptides would
show similar specificity and effects on platelet adherence to human arterial subendothelium under the conditions of high wall shear physiologically present in the microvasculature (20) . At 2,600 s-', our experiments demonstrated significant dosedependent inhibition in platelet adherence with RGDS and GQQHHLGGAKQAGDV (Tables I and II; Fig. 1 ), confirming the results ofprevious studies (29) . The reduction in subendothelial coverage with spread platelets (S) was the predominant finding (Table I and Fig. 1 ). S, measured at a single point in time, reflects a complex interaction between the rate of initial platelet attachment to the surface and the rate at which these attached platelets spread along the subendothelium (30) .
Thus, our morphometric observations may reflect interference by RGDS and GQQHHLGGAKQAGDV with platelet contact, spreading, or both. The maximal reductions of platelet adherence (C + S) observed with RGDS (67%) and GQQHHLGGAKQAGDV (55%) were quite similar to the reductions we found in an earlier study with the anti-GP Ilb-Illa monoclonal antibodies 1OE5 (53%) and PLT-1 (62%) (15) . This suggests that, under the high wall shear perfusion conditions employed, -55-65% of the observed platelet adherence is dependent upon GP Ilb-Illa. This is probably the maximal contribution of GP Ilb-IlIa, since use of GRGDS in concentrations of 150 and 250 gmol/liter failed to cause a further diminution in C + S beyond that seen with 50 qmol/liter RGDS.
Although vWF, Fn, Fg, and GP Ilb-Illa are known to be important in platelet-platelet interactions, little is understood about the nature of the association between vWF, Fn, and GP Ilb-Illa involved in platelet adherence in a flowing system. The interaction of Fg or Fn with GP Ilb-Ila does not appear to be important for platelet adherence (29, 31) . However, recent evidence suggests that binding of vWF to GP Ilb-Illa does play a significant role in platelet adherence and subendothelial thrombus formation (29, 32) . Since amino acid modification in RGD peptides leads to loss of inhibitory activity with respect to platelet adhesive protein binding (Table II) (6, (8) (9) (10) (11) and static platelet adhesion (9) , and the terminal tetrapeptide of GQQHHLGGAKQAGDV also fails to interfere with adhesive protein binding (Table II) (8, 11) , we used modified peptides to examine further the correspondence between standard fluid-phase binding assays and our flowing adhesion system. The presumed mechanism for the contribution of GP Ilb-Illa to platelet adherence involves the binding of subendothelialassociated vWF to the previously described relevant epitope(s) on GP Ilb-IIla. Therefore, it is surprising that RGES, GRADSP, RFDS, KGDS, SDGR, SDGRG, REDV, and AGDV were effective inhibitors of platelet adherence in our experiments performed at a wall shear rate of 2,600 s-' (Tables  I and II) . This inhibition does not appear to be a nonspecific effect of the addition of the peptides, for the control peptides VGSE, LG, and MFM had no effect on platelet adherence (Table I ). The recent observation of Raha et al. (33) (35) . Thus, while Fn interaction with GP Ilb-Ila is not likely to be involved (31), our observation that SDGR (and SDGRG) significantly inhibited platelet adherence to subendothelium at 2,600 s-' (Table  I) provides indirect evidence that VLA-5 may play a role in platelet adherence to subendothelium at high wall shear rates. Our data suggest that the recognition site(s) on the platelet membrane involved at high wall shear rates in platelet adherence to the biochemically heterogenous surface of arterial subendothelium differs significantly in specificity from those that mediate Fg, Fn, and vWF binding to stimulated platelets in the fluid phase or in a static assay system. The specificity of such recognition sites may be shared in part between platelets and fibroblasts (34).
Our studies of platelet adherence to subendothelium at a wall shear rate of 800 s-' demonstrated a significant shear rate dependence of the effects of RGD-and Fg y-chain peptides (Table III) . Not only were the modified peptides without significant inhibitory effects on the platelet-subendothelial interaction, but even RGDS and GQQHHLGGAKQAGDV failed to alter platelet adherence (Table III) The experiments we performed to examine static platelet adhesion to collagen type I provide further evidence for sheardependent differences in platelet-surface interactions. Neither RGDS nor GQQHHLGGAKQAGDV significantly impaired platelet adhesion to collagen, and GRGDSP, RGDT, RGES, KGDS, and SDGRG failed to significantly affect the plateletcollagen interaction. Nievelstein and Sixma (31) failed to observe significant inhibition of platelet adhesion to collagen type I in low shear rate perfusions (300 and 800 s-'), whereas at 1,500 s-' they reported significant inhibition by GRGDSP, but not by GRGESP. The collagen type I surface appears to differ from Fg, Fn, and vWF substrates, in that static platelet adhesion to the latter surfaces is impaired by intact, but not modified, RGD peptides (9), whereas platelet adhesion to collagen is unaffected. Our findings, in conjunction with those of Nievelstein and Sixma (31), suggest that the mechanisms which govern platelet adhesion to collagen at shear rates at or below 800 s-(including static, nonflowing conditions) are distinct from those operative at higher shear rates. Platelet adherence to vascular subendothelium and to collagen appear to be similar in their shear dependence.
In addition to GP Ilb-Ila, platelets contain the adhesive protein receptors, or integrins, VLA-2 (glycoprotein Ia-Ila complex) and VLA-5 (the latter receptor apparently represents the glycoprotein Ic-h1a complex [36] ) (5, (35) (36) (37) (38) (39) (40) (41) (42) (43) . VLA-2 is a collagen receptor (37, 38, 41, 43) , and deficiency of this protein in a patient has been associated with clinical bleeding and profoundly impaired platelet adherence to collagen and human arterial subendothelium (39, 40). VLA-5 constitutes a Fn receptor (35, 42) . GP IIb-IIIa and VLA-5 recognize the RGD sequence (5 A plausible mechanism suggested by our present data and other recent studies is that the adherence of platelets to vascular subendothelium is governed by the following receptor-surface ligand interactions: (a) GP Ib-vWF, (b) GP IIb-IIIa-vWF, (c) GP IIb-IIIa-Vn, (d) VLA-2-collagen, and (e) VLA-5-Fn. At low wall shear rates, addition of RGD-or Fg y-chain carboxyterminal peptides may interfere with the binding of subendothelial-associated vWF, collagen, Fn, and/or Vn to GP Ilb-IIha, VLA-2 and VLA-5, and still the GP Ib-vWF interaction may be sufficient to support normal platelet adherence. In patients deficient in vWF, the interaction between integrin receptor(s) and non-vWF adhesive proteins (i.e., collagen, Fn, and/or Vn) may be adequate to support platelet adherence, accounting for the normal platelet adherence at low wall shear rates observed in patients with von Willebrand's disease. However deficiency, or monoclonal antibody blockade, ofGP lb or GP Ilb-Illa leads to impaired platelet adherence at low wall shear rates (16) . In the case of static platelet adhesion to a collagen substrate in a purified system devoid of vWF, the relevant platelet collagen receptor (e.g., VLA-2) may behave similarly to collagen receptors on other cell types which support adhesion to collagen in the presence of RGDS, but not when exposed to peptides such as GRGDTP which are conformationally more suitable to interfere with the receptor-li-gand interaction (28, 44, 45) . By contrast, at high wall shear rates, RGD-or Fg y-chain peptides may inhibit one or more of the integrin-receptor interactions in b-e described above, and the GP Ib-vWF interaction is inadequate to support normal platelet spreading along the subendothelium (15, 16) (Tables I  and II; Fig. 1 ).
Alternatively, each amino acid in the RGD sequence ofthe subendothelial-associated adhesive protein may be required for platelets subjected to high wall shear to remain attached via the relevant integrin. Exposure of the receptor to peptides in which one of the RGD amino acids is substituted may interfere with the integrin-adhesive protein bond via the nonsubstituted residues. This effect on the receptor may be sufficient to weaken the platelet-subendothelial bond so that platelet adherence is impaired. By contrast, in nonflowing systems, the effect of a substituted peptide to prohibit the binding of one or two of the adhesive protein RGD residues to the integrin may fail to interfere with the overall receptor-ligand association, because the nonblocked residues in the protein may be adequate to maintain the platelet-protein attachment when shear stress is absent. This proposed mechanism implies several testable hypotheses. Future experiments utilizing monoclonal antibodies specific for the various platelet integrins, singly and in combination, reconstituted perfusates deficient in one or more plasma adhesive proteins, and monoclonal antibody treatment of the subendothelial surface should provide much additional insight concerning the shear-dependent receptor-ligand associations important for platelet adherence to subendothelium.
